The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents
Suven Life Sciences has secured patents in Australia (2010360038), Canada (2812970), Japan (5650329) and New Zealand (607658) to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action – H3 Inverse agonist and these patents are valid until 2030. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
With these new patents, Suven has a total of 20 granted patents from Australia, 17 granted patents from Canada, 15 granted patents from Japan and 22 granted patents from New Zealand. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
EP News Bureau – Mumbai